BIM
RGNX icon

Bogle Investment Management’s Regenxbio RGNX Stock Holding History

Bogle Investment Management’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-8,300
Closed -$627K – 407
2018
Q3 		$627K Buy
+8,300
New +$598K 0.05% 229
2018
Q2 		– Sell
-10,567
Closed -$315K – 335
2018
Q1 		$315K Buy
+10,567
New +$308K 0.02% 285

Other funds holding RGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
WM
WS Management Jacksonville, Florida $1.14B AUM 139.27% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Bogle Investment Management's RGNX Position: Q4 2018 in Review

Bogle Investment Management sold out of Regenxbio (RGNX) in Q4 2018, closing a stake of 8,300 shares — an estimated $627K sold.

Bogle Investment Management first reported a position in RGNX in Q1 2018 and held it in 2 quarters. The position peaked at $627K in Q3 2018. 183 funds tracked by Wall St. Rank hold RGNX as of Q4 2018.

  • Bogle Investment Management reported no remaining Regenxbio position as of Q4 2018 after selling out during the quarter.
  • Bogle Investment Management sold 8,300 Regenxbio shares in Q4 2018, an estimated $627K.
  • Bogle Investment Management first reported a position in Regenxbio in Q1 2018 and held it in 2 quarters.
  • Bogle Investment Management's Regenxbio position peaked at $627K in Q3 2018.
  • 183 funds tracked by Wall St. Rank held Regenxbio as of Q4 2018.

Based on Bogle Investment Management's 13F filing for Q4 2018, filed 13 Feb 2019.